IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,297,271 shares of the company's stock after purchasing an additional 37,734 shares during the period. Geode Capital Management LLC owned 2.81% of IDEXX Laboratories worth $948,279,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of IDXX. National Bank of Canada FI grew its stake in IDEXX Laboratories by 17.0% during the 4th quarter. National Bank of Canada FI now owns 73,028 shares of the company's stock valued at $30,193,000 after purchasing an additional 10,592 shares during the last quarter. B. Metzler seel. Sohn & Co. AG boosted its position in IDEXX Laboratories by 57.6% in the fourth quarter. B. Metzler seel. Sohn & Co. AG now owns 14,557 shares of the company's stock valued at $6,018,000 after buying an additional 5,322 shares during the last quarter. Wellington Management Group LLP increased its holdings in IDEXX Laboratories by 161.2% in the 4th quarter. Wellington Management Group LLP now owns 195,369 shares of the company's stock worth $80,773,000 after buying an additional 120,558 shares during the period. Arrowstreet Capital Limited Partnership raised its position in IDEXX Laboratories by 6.5% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 142,192 shares of the company's stock worth $58,788,000 after buying an additional 8,617 shares during the last quarter. Finally, Tsai Capital Corp lifted its stake in IDEXX Laboratories by 52.2% during the 4th quarter. Tsai Capital Corp now owns 8,797 shares of the company's stock valued at $3,637,000 after acquiring an additional 3,016 shares during the period. Hedge funds and other institutional investors own 87.84% of the company's stock.

Remove Ads

Insider Activity

In related news, EVP George Fennell sold 9,986 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded down $17.03 during trading hours on Friday, reaching $393.73. The company's stock had a trading volume of 1,635,645 shares, compared to its average volume of 592,305. The firm has a market capitalization of $31.91 billion, a price-to-earnings ratio of 36.90, a P/E/G ratio of 3.41 and a beta of 1.39. The company's 50-day moving average is $435.55 and its two-hundred day moving average is $440.31. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 1-year low of $390.11 and a 1-year high of $548.88.

Analysts Set New Price Targets

IDXX has been the topic of a number of research reports. Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Tuesday, March 25th. Finally, Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.